{"id":"halobetasol-topical-lotion","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Striae"},{"rate":null,"effect":"Telangiectasia"},{"rate":null,"effect":"Folliculitis"},{"rate":null,"effect":"Hypertrichosis"},{"rate":null,"effect":"Acneiform eruptions"},{"rate":null,"effect":"Hypopigmentation"}]},"_chembl":{"chemblId":"CHEMBL1200908","moleculeType":"Small molecule","molecularWeight":"484.97"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Halobetasol propionate is a Class I (super-potent) corticosteroid that penetrates skin tissue and binds to intracellular glucocorticoid receptors, leading to decreased production of inflammatory mediators, reduced immune cell infiltration, and suppression of local inflammatory responses. This mechanism makes it effective for treating severe inflammatory and allergic skin conditions.","oneSentence":"Halobetasol is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:22:44.786Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses"},{"name":"Severe dermatitis, psoriasis, and lichen planus (topical)"}]},"trialDetails":[{"nctId":"NCT05608499","phase":"PHASE3","title":"Duobrii Treatment of Acne Keloidalis Nuchae (AKN)","status":"TERMINATED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2022-10-26","conditions":"Acne Keloidalis Nuchae, AKN","enrollment":15},{"nctId":"NCT05203315","phase":"PHASE3","title":"Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults","status":"COMPLETED","sponsor":"Austin Institute for Clinical Research","startDate":"2022-01-13","conditions":"Plaque Psoriasis","enrollment":21},{"nctId":"NCT06015152","phase":"NA","title":"Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis","status":"COMPLETED","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2022-08-01","conditions":"Scalp Psoriasis","enrollment":90},{"nctId":"NCT05282771","phase":"EARLY_PHASE1","title":"A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2021-04-16","conditions":"Plaque Psoriasis","enrollment":402},{"nctId":"NCT03212963","phase":"PHASE4","title":"Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%","status":"TERMINATED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2017-03-21","conditions":"Plaque Psoriasis","enrollment":16},{"nctId":"NCT02515097","phase":"PHASE3","title":"Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2015-11-05","conditions":"Plaque Psoriasis","enrollment":213},{"nctId":"NCT02514577","phase":"PHASE3","title":"Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2015-11-07","conditions":"Plaque Psoriasis","enrollment":217},{"nctId":"NCT00990561","phase":"PHASE4","title":"Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-07","conditions":"Stable Plaque Psoriasis","enrollment":40},{"nctId":"NCT01111123","phase":"PHASE4","title":"Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2009-01","conditions":"Plaque Psoriasis","enrollment":55},{"nctId":"NCT01166646","phase":"PHASE2","title":"Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Therapeutics, Inc.","startDate":"2010-07","conditions":"Plaque Psoriasis","enrollment":43},{"nctId":"NCT01610596","phase":"PHASE2","title":"A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis","status":"COMPLETED","sponsor":"Therapeutics, Inc.","startDate":"2011-11","conditions":"Psoriasis, Plaque Psoriasis","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Halobetasol topical lotion 0.05%"],"phase":"marketed","status":"active","brandName":"Halobetasol Topical Lotion","genericName":"Halobetasol Topical Lotion","companyName":"Sun Pharmaceutical Industries Limited","companyId":"sun-pharmaceutical-industries-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Halobetasol is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Severe dermatitis, psoriasis, and lichen planus (topical).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}